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Background: Maintenance of mucosal healing is recommended during the treatment of 
ulcerative colitis (UC). However, symptoms of UC often do not reflect mucosal disease 
activity. Fecal markers such as calprotectin, lactoferrin, and hemoglobin have been 
reported to correlate well with the Mayo endoscopic subscore (MES) and are being 
considered alternative monitoring tools in endoscopy. Ulcerative Colitis Endoscopic 
Index of Severity (UCEIS) is a new and more detailed endoscopic scoring system 
compared to MES. Furthermore, magnifying endoscopic stratification (ME) based on 
alterations in the mucosal surface pit patterns is noted in UC. However, the association 
between fecal markers and UCIES and magnifying endoscopy is relatively unexplored. 
Summary: This study investigated the association between the aforementioned fecal 
markers and MES, UCEIS, and ME in patients with UC in clinical remission. This 
prospective study included 60 patients with UC in clinical remission who underwent 
colonoscopy at the Nagasaki University Hospital between June 2015 and November 
2016. A significant correlation was observed between MES and all fecal markers. 
Notably, the fecal markers correlated well with UCEIS (calprotectin Spearman’s 
correlation coefficient [r]=0.54, P<0.0001; lactoferrin r=0.56, P<0.0001; and hemoglobin 
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r=0.43, P<0.001). Furthermore, ME findings correlated significantly with calprotectin 
(r=0.50, P=0.0002) and lactoferrin (r=0.46, P=0.0006) levels and slightly with 
hemoglobin (r=0.28, P=0.043) levels. Moreover, each cut-off level of fecal calprotectin, 
lactoferrin, or hemoglobin had a high sensitivity and specificity for the detection of 
MES=0, UCEIS=0, ME=A, for predicting mucosa healing. 
Key Messages: Fecal markers correlated not only with MES but also with UCEIS and 















Ulcerative colitis (UC) is a chronic, idiopathic, inflammatory bowel disease that 
causes diffuse inflammatory mucosal damage, causing erosions and ulcers in the colon, 
especially in the rectum. The disease has a lifelong clinical course characterized by the 
repeat of relapse and remission. The main purpose of therapy in UC is to suppress 
mucosal inflammation and induce and sustain clinical remission. Recent evidence 
recommends sustained endoscopic remission, which is associated with improved 
outcomes for UC [1, 2]. Importantly, patient symptoms often do not reflect mucosal 
disease activity. Consequently, to evaluate disease activity and therapeutic efficacy, 
clinical symptoms and laboratory and endoscopic findings need to be monitored 
routinely in clinical practice [3]. Currently, colonoscopy is the most effective means of 
estimating of UC severity. However, colonoscopy is burdensome, invasive, and costly for 
patients, and requires the diagnostic skills of the endoscopist. Because frequent 
colonoscopy is not realistic for UC patients, the development of non-invasive surrogate 
markers is necessary.  
Fecal markers such as calprotectin, lactoferrin, and hemoglobin have been reported to 
correlate well with the Mayo endoscopic subscore (MES) and are being considered  
alternative monitoring tools in endoscopy [4-8]. Calprotectin is a calcium-binding 
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protein and accounts for up to 60% of cytoplasmic proteins in neutrophils [6], and is 
mainly derived from neutrophils. Fecal calprotectin concentration is reported to be 
associated with the concentration of neutrophils in the colonic mucosa [9]. It is 
convenient to handle since calprotectin is stable in the feces for up to 1 week at room 
temperature [6, 10]. Lactoferrin is an iron-binding glycoprotein secreted from most 
mucosal membranes and is also a major component of neutrophils [5, 11, 12]. When 
inflammation occurs in the intestinal tract, leucocytes enter the mucosa and this may 
increase the excretion of lactoferrin in stool. Lactoferrin is also convenient to handle 
since it is relatively stable in the stool for up to 4 days [13, 14]. 
The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is a newly 
proposed and more detailed endoscopic scoring system compared to MES [15]. In 
addition to the more detailed scoring of the extent of ulcers compared to MES, UCIES 
includes the degree of vascular appearance. Indeed, it has been reported that UCEIS 
precisely reflects clinical outcomes and predicts the medium-to-long-term prognosis in 
UC patients on induction therapies [16]. However, only few studies have examined the 
association between fecal markers and UCEIS [17]. Furthermore, we recently proposed 
a magnifying endoscopic stratification (ME) based on alterations in the mucosal surface 
pit patterns, which are associated not only with the Matts endoscopic score but also 
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with pathognomonic microscopic features of mucosal inflammation [18]. Notably, we 
also demonstrated its utility in predicting relapse in patients with UC [18]. However, 
the association between fecal surrogate markers and UCIES or ME has not been 
studied.  
The aim of our study was to investigate the correlation of fecal calprotectin, 
lactoferrin, and hemoglobin levels with MES, UCEIS and ME in patients with UC in 
clinical remission.  
 
Material and Methods 
Study Design and Patients 
This prospective study included 60patients with UC in clinical remission who 
underwent colonoscopy at the Nagasaki University Hospital between June 2015 and 
November 2016. The inclusion criteria were as follows: UC patients diagnosed with 
established criteria, aged ≥ 20 years, and in clinical remission. The exclusion criteria 
were active UC, pregnancy, liver, kidney, and heart disease, and other severe 
complications. Clinical remission was defined as a partial UC disease activity index of 
≤2 and a bloody stool score of 0 [19]. 
Measurement of Fecal Calprotectin, Lactoferrin, and Hemoglobin Levels 
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Stool samples were collected before colonoscopy on the same day. The collected feces 
were stored at room temperature and immediately analyzed at the Kyoto Medical 
Science Laboratory (Kyoto, Japan). Fecal lactoferrin was measured using sandwich 
enzyme-linked immunosorbent assay, previously described in detail [20]. Fecal 
calprotectin level was measured using an enzyme-linked immunosorbent assay kit 
(Immunodiagnostik AG, Benshem, Germany). Hemoglobin level was measured using 
the Nescauto hemo plus (Alfresa Pharma Corporation, Japan). 
Ulcerative Colitis Endoscopic Index of Severity  
MES, UCEIS, and ME were evaluated during the same session of colonoscopy. Scores 
and classifications were determined by the agreement of two experienced endoscopists. 
The UCEIS score is based on a visual analog scale represented by incorporating a 
combination of 3 elements: vascular pattern (2 levels), bleeding (3 levels), and erosions 
and ulcers (3 levels). Via colonoscopy, the worst state of the colon is identified, and the 
score may be calculated by adding the scores from each section ranging from 0 (normal) 
to 8 (worst) [17]. 
Magnifying Endoscopic Stratification 
ME observations were performed at the location where the most severe inflammation 
was detected during white light examination. For cases without apparent inflammation, 
9 
 
ME was performed in the rectal mucosa. The endoscopy system consisted of a light 
source (CLV-260SL; Olympus Optical Co., Tokyo, Japan), a colonoscope (PCF-Q260AZI; 
Olympus), and a processor (CV-260SL; Olympus). On insertion of the colonoscope, 
luminal cleansing was performed using water with dimethicone and pronase. After 
standard observation, in the rectal mucosa, ME was performed following vital staining 
including 0.05% crystal violet. ME findings were classified into 4 grades: ME-A, regular 
arrangement of normal round-to-oval pits; ME-B, irregular arrangement of the 
round-to-oval pits with/without enlarged spaces between the even crypts; ME-C, 
irregular pits in size and shape with a more irregular arrangement of the pits compared 
to ME-B; and ME-D, destruction and disappearance of pits, as previously described by 
Isomoto et al [18]. 
Statistical Analysis 
Statistical analyses were performed using JMP version 11.0 for Windows (SAS Institute, 
Cary, NC, USA). Sensitivity and specificity with 95% confidence intervals for finding 
MES, UCEIS, and ME levels were established according to calprotectin, lactoferrin, and 
hemoglobin results. We analyzed the receiver operating characteristic (ROC) curve and 
the area under the curve (AUC) to evaluate the appropriate cut-off values for 
calprotectin, lactoferrin, and hemoglobin. Moreover, we conducted the Spearman’s rank 
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correlation test to clarify the correlation between calprotectin, lactoferrin, and 
hemoglobin levels and MES, UCEIS, and ME. p-values < 0.05 were considered 
statistically significant. 
Ethical Considerations 
The study was approved by the Nagasaki University Ethics Committee (Number：
16020830) and was conducted in accordance with the Helsinki Declaration. Informed 
consent was acquired from all patients in advance regarding the use of their fecal 
samples and clinical data for this study. 
 
Results 
Clinical Characteristics of Patients (Table 1) 
The total number of 60 patients consisted of 35 men and 25 women. The median patient 
age was 51. Among the 60 UC patients, 40 (67%) had extensive colitis, 13 (22%) had 
left-sided colitis, and 7 (12%) had proctitis. For remission maintenance therapy, 
salazosulfapyridine was used in 5 patients, mesalamine in 43 patients, 
azathioprine/mercaptopurine in 13 patients, infliximab/adalimumab in 5 patients, and 




Of the 60 cases, 18 cases (30%) had a MES score of 0, 27 cases (45%) had a MES score of 
1, and 15 (25%) cases had a MES score of 2. Seventy percent (42/60) of patients in 
clinical remission had ongoing endoscopic inflammation (MES≥1). 
Of the 60 cases, 16 cases (27%) had a UCEIS score of 0, 20 cases (33%) had a UCEIS 
score of 1, 7 (11%) cases had a UCEIS score of 2, 8 (13%) cases had a UCEIS score of 3, 7 
(12%) cases had a UCEIS score of 4, 1 (1.7%) case had a UCEIS score of 5, and 1 (1.7%) 
case had a UCEIS score of 6. 
Of the 60 cases, 52 cases underwent ME. According to ME stratification, there were 21 
cases of ME-A, 17 cases of ME-B, 12 cases of ME-C, and 2 cases of ME-D (Table 2). 
Relationship between Calprotectin, Lactoferrin, Hemoglobin, and Colonoscopic 
Findings 
A significant correlation was observed between MES and all fecal markers (Spearman’s 
correlation coefficient [r] for calprotectin = 0.34, P < 0.01; lactoferrin r = 0.45, P < 0.01; 
and hemoglobin r = 0.38, P < 0.01) and between UCEIS and all fecal markers 
(calprotectin r = 0.54, P < 0.0001; lactoferrin r = 0.56, P < 0.0001; and hemoglobin r = 
0.43, P < 0.001) (Figure 1a). Furthermore, ME findings correlated significantly with 
calprotectin and lactoferrin levels and slightly with hemoglobin levels (calprotectin r = 
0.50, P < 0.001; lactoferrin r = 0.46, P < 0.001; and hemoglobin r = 0.28, P = 0.043) 
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(Figure 1b). In addition, a significant correlation was observed between ME and UCEIS 
(r = 0.74, P < 0.0001). These results suggest that fecal markers correlate not only with 
MES but also with UCEIS and ME.  
Receiver Operating Curve Analysis and the Predictive Ability of Fecal Markers 
Calprotectin, at a cut-off of 201 µg/ml, had a sensitivity of 71% and specificity of 78% for 
the detection of MES=0 (prediction of mucosal healing) (AUC 0.77). Lactoferrin (cut-off 
78.3 ng/ml) had a sensitivity of 60% and specificity of 89% for the detection of MES=0 
(AUC 0.73). Hemoglobin (cut-off 34 ng/ml) had a sensitivity of 64% and specificity of 
89% for the detection of MES=0 (AUC 0.76). Calprotectin, at a cut-off of 201 µg/ml, had 
a sensitivity of 70% and specificity of 81% for the detection of UCEIS=0 (prediction of 
mucosal healing) (AUC 0.76). Lactoferrin (cut-off 78.3 ng/ml) had a sensitivity of 57% 
and specificity of 88% for the detection of UCEIS=0 (AUC0.71). Hemoglobin (cut-off 31 
ng/ml) had a sensitivity of 64% and specificity of 88% for the detection of UCEIS=0 
(AUC 0.74) (Figure 2a). Calprotectin, at a cut-off of 280 µg/ml, had a sensitivity of 68% 
and specificity of 86% for the detection of ME=A (prediction of mucosal healing) (AUC 
0.78). Lactoferrin (cut-off 43.6 ng/ml) had a sensitivity of 71% and specificity of 76% for 
the detection of ME=A (AUC 0.77). Hemoglobin (cut-off 34 ng/ml) had a sensitivity of 
71% and specificity of 86% for the detection of ME=A (AUC 0.78) (Figure 2b). These 
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results suggest that fecal markers are useful for monitoring patients with UC in clinical 
remission.  
Detection of the Inflammation in Right-Side Colon  
In 10 of the 40 patients with extensive colitis, endoscopic inflammation remained only 
in the right side of the colon. In these 10 cases, calprotectin, lactoferrin, and hemoglobin, 
at a cut-off value (for detecting UCEIS=0 i.e. the prediction of mucosal healing) of 201 
µg/ml, 78.3 ng/ml, and 31 ng/ml, respectively, had a sensitivity of 100% (10/10), 70% 
(7/10), and 50% (5/10), respectively. No significant difference was found between the 
markers. This result suggests that calprotectin could be a highly sensitive tool for 
detecting inflammation in the right side of the colon. 
 
Discussion 
 In this study, although all the patients were in clinical remission, 70% (42/60) 
of patients had ongoing endoscopic inflammation, including 25% cases with a MES score 
of 2. Our results suggest that patients with active intestinal inflammation occasionally 
have no symptoms or may fail to report symptoms. Therefore, monitoring symptoms 
alone lead to under-treatment of the disease and a higher likelihood of clinical 
recurrence. Recently, the importance of achieving mucosal healing, rather than 
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symptoms elimination alone, has been recognized [21]. Moreover, it has been reported 
that patients who achieve mucosal healing have lower rates of hospitalization and a 
lower risk of colectomy [1, 2]. Furthermore, in UC patients, a prolonged disease course 
and immunosuppressive therapy increase the risk for emerging malignancies compared 
to those who have a normal colon [22-24].  
Recently, fecal markers have received attention as means for the noninvasive 
monitoring of disease activity. Several studies have reported that fecal markers such as 
calprotectin, lactoferrin, and hemoglobin correlate well with MES [4, 25, 26], but only 
few studies have examined the association between fecal markers and UCEIS [17]. In 
this study, we confirmed the correlation of fecal calprotectin, lactoferrin, and 
hemoglobin with MES or UCEIS in patients with UC in clinical remission. Surface pit 
pattern classification with ME is known to have a good association with the 
histopathological diagnosis of colorectal tumor [18]. Similarly, recent studies have 
shown that ME findings are significantly correlated with histological grades [27, 28]. Of 
note, it is reported that ME could be useful in assessing microscopic inflammatory 
features of UC that cannot be determined by white light colonoscopic examination [27, 
28]. The use of ME in UC is relatively new and different ME classifications have been 
proposed to date [18, 27, 28]. Further studies are required to determine the 
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classifications that most accurately represent and predict the patient’s clinical status 
and outcome. This study is the first to report that fecal calprotectin and lactoferrin 
levels are significantly correlated with ME grade in patients with UC in clinical 
remission. Moreover, the cut-off levels of fecal calprotectin, lactoferrin, or hemoglobin 
had a high sensitivity and specificity for the detection of MES=0, UCEIS=0, ME=A.  
Therefore, fecal markers should be considered as alternative monitoring tools in 
endoscopy and could provide an opportunity for recommending colonoscopy to patients 
with UC in clinical remission. 
 In the 10 cases with extensive colitis involving macroscopic inflammation on 
the right side of the colon alone, fecal calprotectin, lactoferrin, and hemoglobin, at a 
cut-off value for detecting UCEIS=0, had a sensitivity of 100% (10/10), 70% (7/10), and 
50% (5/10), respectively. It is reported that hemoglobin tends to lose antigenicity 
because of its degradation by fecal bacteria and digestive enzymes [29]. Moreover, the 
stability of calprotectin in the feces is also reported to be greater than that of lactoferrin 
[6, 14]. Our results suggest that calprotectin could have a superior sensitivity, compared 
to other fecal markers, for the detection of inflammation on the right side of the colon, 
although the small sample size may have masked the true differences. 
Reports show that in patients with UC, regulation of the 5-aminosalicylic acid 
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(ASA) dose, with the monitoring of fecal calprotectin levels, resulted in significantly 
lower relapse rates compared to the control group [30, 31]. Isomoto et al. demonstrated 
significant differences in the percentages of relapse of UC among the ME grades 
retrospectively. Our prospective study is ongoing, to analyze whether ME findings can 
predict relapse in UC. When future relapse of UC is predicted by fecal markers and 
colonoscopy findings, it may be possible to take preventive measures such as increasing 
5-ASA dosage before symptoms appear and, thus, exclude complications and the 
progression to intractable cases. 
In conclusion, our analysis demonstrated that fecal markers correlated not only 
with MES but also with UCEIS and ME and may be useful for monitoring patients with 
UC in clinical remission. Moreover, we suggest that calprotectin is a highly sensitive 
tool for detecting macroscopic inflammation on the right side of the colon. Additional 
prospective studies are required to ascertain whether fecal markers can be used as an 
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Figure 1a. Correlation between UCEIS and fecal markers 
The relationships between calprotectin, lactoferrin, hemoglobin, and UCEIS were 
analyzed. A significant correlation was observed between UCEIS and all fecal markers 
(Spearman’s rank correlation coefficient for calprotectin r = 0.54, P < 0.0001; lactoferrin 
r = 0.56, P < 0.0001; and hemoglobin r = 0.43, P < 0.001). FC: fecal calprotectin; Lf: 
lactoferrin; UCEIS: Ulcerative Colitis Endoscopic Index of Severity 
 
Figure 1b. Correlation between ME and fecal markers 
The relationship between calprotectin, lactoferrin, hemoglobin, and ME were analyzed. 
ME correlated significantly with calprotectin and lactoferrin levels but slightly with 
hemoglobin levels (calprotectin r = 0.50, P < 0.001; lactoferrin r = 0.46, P < 0.001; and 
hemoglobin r = 0.28, P = 0.043). FC: fecal calprotectin; Lf: lactoferrin; ME: magnifying 
endoscopic stratification 
 
Figure 2a. Receiver operating curve analysis for the fecal markers (for differentiating 
between UCEIS=0 and ≥1) 
Calprotectin, at a cut-off of 201 μg/ml, had a sensitivity of 70% and specificity of 81% for 
the detection of UCEIS=0 (prediction of mucosal healing) (AUC 0.76). Lactoferrin 
(cut-off 78.3 ng/ml) had a sensitivity of 57% and specificity of 88% for the detection of 
UCEIS=0 (AUC 0.71). Hemoglobin (cut-off 31 ng/ml) had a sensitivity of 64% and 
specificity of 88% for the detection of UCEIS=0 (AUC 0.74). FC: fecal calprotectin; Lf: 
lactoferrin; UCEIS: Ulcerative Colitis Endoscopic Index of Severity 
 
Figure 2b. Receiver operating curve analysis for the fecal markers (for differentiating 
between ME=A and ≥B) 
Calprotectin, at a cut-off of 280 μg/ml, had a sensitivity of 68% and specificity of 86% for 
the detection of ME=A (prediction of mucosal healing) (AUC 0.78). Lactoferrin (cut-off 
43.6 ng/ml) had a sensitivity of 71% and specificity of 76% for the detection of ME=A 
(AUC 0.77). Hemoglobin (cut-off of 34 ng/ml) had a sensitivity of 71% and specificity of 
86% for the detection of ME=A (AUC 0.78). FC: fecal calprotectin; Lf: lactoferrin; ME: 
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r = 0.56, P < 0.0001; and hemoglobin r = 0.43, P < 0.001). FC: fecal calprotectin; Lf: 





Figure 1b. Correlation between ME and fecal markers 
The relationship between calprotectin, lactoferrin, hemoglobin, and ME were analyzed. 
ME correlated significantly with calprotectin and lactoferrin levels but slightly with 
hemoglobin levels (calprotectin r = 0.50, P < 0.001; lactoferrin r = 0.46, P < 0.001; and 






Figure 2a. Receiver operating curve analysis for the fecal markers (for differentiating 
between UCEIS=0 and ≥1) 
Calprotectin, at a cut-off of 201 μg/ml, had a sensitivity of 70% and specificity of 81% for 
the detection of UCEIS=0 (prediction of mucosal healing) (AUC 0.76). Lactoferrin 
(cut-off 78.3 ng/ml) had a sensitivity of 57% and specificity of 88% for the detection of 
UCEIS=0 (AUC 0.71). Hemoglobin (cut-off 31 ng/ml) had a sensitivity of 64% and 
specificity of 88% for the detection of UCEIS=0 (AUC 0.74). FC: fecal calprotectin; Lf: 







Figure 2b. Receiver operating curve analysis for the fecal markers (for differentiating 
between ME=A and ≥B) 
Calprotectin, at a cut-off of 280 μg/ml, had a sensitivity of 68% and specificity of 86% for 
the detection of ME=A (prediction of mucosal healing) (AUC 0.78). Lactoferrin (cut-off 
43.6 ng/ml) had a sensitivity of 71% and specificity of 76% for the detection of ME=A 
(AUC 0.77). Hemoglobin (cut-off of 34 ng/ml) had a sensitivity of 71% and specificity of 
86% for the detection of ME=A (AUC 0.78). FC: fecal calprotectin; Lf: lactoferrin; ME: 















Table 1. Characteristics of patients 
 
Patients  
   Total 60 
   Age [Median (range)] years  51 (20-79) 
Gender  
   Male 35 (58%) 
   Female 25 (42%) 
Extent of inflammation  
   Extensive colitis 40 (67%) 
   Left-sided colitis 13 (22%) 
   Proctitis 7 (12%) 
Concomitant medications  
   None 6 
   Salazosulfapyridine 5 
   Mesalamine 43 
   Azathioprine / Mercaptopurine 9 / 4 








Table 2. Summary of the relationship between magnifying endoscopic (ME) 














ME-A  (n=21) 15 6     
ME-B  (n=17)  9 4 3 1  
ME-C  (n=12)  3 2 4 3  
ME-D  (n=2)    1  1 
 
A significant correlation was observed between ME and UCEIS (r = 0.74, P < 0.0001). 
